GlassScriptPhysician profile
Kayla Smith
NPI 1164003539
$1,313.57
in general payments reported to CMS, 2019-2025
23 companies · $616 in 2025
The $616 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $38.26 · 2024: $660 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.46 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $190.42 | 2024-2025 | Rybrevant, Darzalex, Talvey |
| Incyte Corporation | $149.49 | 2023-2025 | Monjuvi, Pemazyre, Jakafi |
| Novartis Pharmaceuticals Corporation | $127.64 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $106.24 | 2024-2025 | Keytruda, Reblozyl, Welireg |
| Regeneron Healthcare Solutions, INC. | $87.21 | 2024-2025 | Libtayo |
| Genzyme Corporation | $78.84 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.32 | 2024-2025 | Ninlaro, Fruzaqla |
| Genentech USA, INC. | $54.81 | 2024-2025 | Polivy, Columvi, Lunsumio |
| Astrazeneca Pharmaceuticals LP | $53.93 | 2024-2025 | Calquence, Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $51.79 | 2024-2025 | Opdivo |
| Eisai INC. | $50.15 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $39.38 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $37.28 | 2024-2025 | Cosela, Monoferric |
| Puma Biotechnology, INC. | $32.10 | 2024 | |
| Pfizer INC. | $32.10 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $22.30 | 2024 | Somatuline Depot, Onivyde |
| Jazz Pharmaceuticals INC. | $20.37 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.66 | 2025 | |
| Abbvie INC. | $18.11 | 2024 | |
| Glaxosmithkline, LLC. | $17.44 | 2024 | Zejula, Jemperli |
| Emd Serono, INC. | $15.41 | 2025 | |
| Atricure, INC. | $14.93 | 2024 | |
| Array Biopharma INC | $13.56 | 2025 | Padcev, Lorbrena, Braftovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.